APL whitepaper: It is never too early to think “drug product”
community download

APL whitepaper: It is never too early to think “drug product”

information we require

please check before submitting



Unfortunately the document is not available at this current time, however if you leave your details we'll get it to you as soon as we can.

Please fill in all the information requested. It is very important you enter this information correctly so we can contact you with the document.

Privacy statement »

Manage your email preferences »

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details

Key features of drug product formulation:

The orphan drug product (DP) you develop is what the patients will encounter and what medicinal agencies will approve. What you develop will most probably influence patients’ lives in a tremendous way, potentially curing them and improving quality of their lives like nothing else has done before. The formulation of the DP will thus play a big role in how patients perceive the drug, how it becomes a part of their lives, and how they structure their life around it.

 

The formulation you choose will influence following key features of your DP:

  •  Efficacy: DP is absorbed in a body and acts in line with its purpose
  •  Safety: DP is non-toxic for patients, minimizes risk for local side effects and may adjust for therapeutic windows of drug substance
  •  Stability: Drug substance does not decompose
  •  Uniformity of dosage: Same dosage with same effect is administered at every occasion
  •  Appearance: DP is compliant to patients
  •  Price: The cost of the final product is accepted by healthcare systems
  •  Patient acceptability: It is easy to use and dose the product both by patients and potentially healthcare providers
  •  Patentability: The formulation provides novelty, rising possibility to protect your invention for a certain part of its commercial lifetime.